Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Hydrogen Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumption

NCT06724705
View directory record Official record
Conditions
Lactose Intolerance, Adult Type
Interventions
Lactose, Sucrose, Wear smart underwear
Dietary Supplement · Device
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

NCT05954286
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Upamostat, Placebo (PO)
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

DMT310-003 Topical in the Treatment of Acne Vulgaris

NCT04106778
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 30, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

NCT02452463
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Durvalumab, Nintedanib, Placebo, Quality-of-Life Assessment
Biological · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 30, 2026, 11:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

NCT00433511
View directory record Official record
Conditions
Breast Adenocarcinoma
Interventions
Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4,994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
840
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443820
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Sep 30, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mouth Rinses for Inactivation of COVID-19

NCT04584684
View directory record Official record
Conditions
Covid19, Coronavirus Infection, SARS-CoV-2 Infection
Interventions
0.9% w/v NaCL Saline, 1.5% w/v Hydrogen Peroxide, 0.12% Chlorohexidine Gluconate, 27% Ethanol plus essential oils, 0.5% w/v Povidone-iodide, 0.075% Cetylpyridinium Chloride
Other · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 30, 2026, 11:27 AM EDT
Recruiting Not applicable Interventional

Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT07753122
View directory record Official record
Conditions
Chronic Fatigue Syndrome (CFS)
Interventions
Placebo condition, Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.
Dietary Supplement
Lead sponsor
Fred Friedberg
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Sodium Nitroprusside in Early Course Schizophrenia

NCT04986072
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sodium Nitroprusside, 5% Dextrose solution
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia

NCT02164981
View directory record Official record
Conditions
Schizophrenia
Interventions
sodium nitroprusside, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 30, 2026, 11:27 AM EDT
Not yet recruiting Phase 2 Interventional

Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome

NCT07768267
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Biocidin REMOVE, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis

NCT00691184
View directory record Official record
Conditions
Onychomycosis/Onycholysis and Tinea Pedis
Interventions
Placebo, Terbinafine Hydrochloride, Terbinafine
Drug
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Results available

Glycemic Effect of Diazoxide in NAFLD

NCT05729282
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Interventions
Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O)
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

NCT00942331
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Interventions
Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
872
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

Ketamine and Nitroprusside for Depression

NCT03102736
View directory record Official record
Conditions
Depression
Interventions
Placebos, Ketamine, Nitroprusside
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT02292758
View directory record Official record
Conditions
Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria in Saliva and Bioaerosol Contamination

NCT04626778
View directory record Official record
Conditions
Healthy
Interventions
Peroxyl Mouthwash, Placebo Mouthwash
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Neuroprotection in Acute Ischemic Stroke

NCT03320018
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 30, 2026, 11:27 AM EDT
Withdrawn Phase 1 Interventional

Oxaloacetate in Myasthenia Gravis

NCT04965987
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Oxaloacetate, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Alpha Hope Dietary Supplement on Health and Cognitive Performance

NCT05589051
View directory record Official record
Conditions
Cognitive Change
Interventions
Drink
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
40 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Sep 30, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

NCT05997277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide
Radiation · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

NCT00956397
View directory record Official record
Conditions
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
Interventions
Rifaximin, Lactulose Breath Test, Placebo
Drug · Procedure
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 30, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00886691
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
45
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Sep 30, 2026, 11:27 AM EDT